Stocks / NASDAQ / Neos Therapeutics, Inc.

Neos Therapeutics, Inc.

Our Opinion

Neos Therapeutics, Inc. is on the Cruelty Free Investing use of animals list because they use animals for drug testing and clinical trials.

Supporting Evidence:

The company announced that the U.S. Food and Drug Administration (FDA) approved Adzenys XR-ODT™ for the treatment of ADHD in patients six years and older.

“Use only if the potential benefit justifies the potential risk to the fetus. Based on animal data, Adzenys XR-ODT may cause fetal harm.” Read the following article

Company Description

Neos Therapeutics, Inc. operates as a pharmaceutical company, which engages in developing, manufacturing, and commercializing products using proprietary, extended-release drug delivery technology platform. It uses this technology to develop products for the treatment of attention deficit hyperactivity disorder (ADHD), including an extended-release orally disintegrating tablet. The company was founded on June 15, 2009 and is headquartered in Grand Prairie, TX. [Source: MarketWatch]

Company Website: